# P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

> **NCT05905055** · PHASE3 · COMPLETED · sponsor: **Meiji Seika Pharma Co., Ltd.** · enrollment: 126 (actual)

## Conditions studied

- Complicated Urinary Tract Infection
- Acute Pyelonephritis
- Hospital-acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
- Complicated Intra-abdominal Infection

## Interventions

- **DRUG:** co-administration of cefepime and nacubactam
- **DRUG:** co-administration of aztreonam and nacubactam
- **DRUG:** BAT

## Key facts

- **NCT ID:** NCT05905055
- **Lead sponsor:** Meiji Seika Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-22
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905055, "P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05905055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*